A5100722759- Intracerebral and Subarachnoid Hemorrhage Research
- Lung Cancer Treatments and Mutations
- Neurosurgical Procedures and Complications
- Salivary Gland Tumors Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Acute Ischemic Stroke Management
- HER2/EGFR in Cancer Research
- Ear and Head Tumors
- Lung Cancer Diagnosis and Treatment
- Spinal Hematomas and Complications
- Antiplatelet Therapy and Cardiovascular Diseases
- Cancer, Hypoxia, and Metabolism
- Radiomics and Machine Learning in Medical Imaging
- Urticaria and Related Conditions
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Pancreatic and Hepatic Oncology Research
- Systemic Lupus Erythematosus Research
- Radiopharmaceutical Chemistry and Applications
- Bipolar Disorder and Treatment
- Gastric Cancer Management and Outcomes
- Tumors and Oncological Cases
- Cancer, Lipids, and Metabolism
- Head and Neck Cancer Studies
- interferon and immune responses
- Medical Imaging Techniques and Applications
Shanghai University of Traditional Chinese Medicine
2024-2025
Seventh People's Hospital of Shanghai
2024-2025
Renji Hospital
2025
Shanghai Jiao Tong University
2025
The University of Texas MD Anderson Cancer Center
2021-2024
Beijing Friendship Hospital
2024
Capital Medical University
2021-2024
The University of Texas Health Science Center at Houston
2024
Qiqihar Medical University
2024
Weatherford College
2024
Amivantamab-vmjw (amivantamab) is a bispecific EGFR/MET antibody approved for patients with advanced NSCLC EGFR exon 20 insertion mutations, after prior therapy. Nevertheless, the benefits and safety of amivantamab in other EGFR-mutant lung cancer, or without osimertinib, concurrent radiation therapy, are less known. We queried MD Anderson Lung Cancer GEMINI, Fred Hutchinson Research Center, University California Davis Comprehensive Stanford Center's database treated amivantamab, not on...
Objective The aim of this study was to investigate the bidirectional causal relationship between sex hormones and IBD through a two-sample Mendelian randomization (MR) study. Methods Based on Genome-Wide Association Study (GWAS) pooled data SHBG, total testosterone, bioavailable estradiol, in European population, we performed MR analyses using single nucleotide polymorphisms (SNPs) as instrumental variables. We used inverse variance weighting (IVW), weighted median, mode, MR-Egger assess...
Secretion of ligands the human epidermal growth factor (EGFR) family receptors or erythroblastic leukemia viral oncogene (ERBB1-4) is a feature common to many cancer cells. However, our understanding role autocrine in aberrant behavior remains incomplete. Here we demonstrate that, numerous preclinical models lung tumorigenesis, BRAFV600E signaling promotes expression including HB-EGF, TGF Alpha;, Epi- and Amphiregulin. Moreover, using both genetic pharmacological approaches, that...
MET amplification is a known resistance mechanism to EGFR tyrosine kinase inhibitor (TKI) treatment in EGFR-mutant NSCLC. Dual EGFR-MET inhibition has been reported with success overcoming such and inducing clinical benefit. Resistance mechanisms dual require further investigation characterization.Patients NSCLC both mutation who have received crizotinib, capmatinib, savolitinib, or tepotinib plus osimertinib (OSI) after progression on OSI at MD Anderson Cancer Center were included this...
Background Salivary duct carcinoma (SDC) and adenocarcinoma, not otherwise specified (adeno‐NOS), are rare salivary gland cancers. Data on the efficacy of systemic therapy for these diseases limited. Methods were retrospectively collected from patients seen at The University Texas MD Anderson Cancer Center during 1990 to 2020. Objective response rate (ORR) was assessed per RECIST v1.1. Recurrence‐free survival (RFS), progression‐free (PFS), overall (OS) by Kaplan‐Meier method. Cox regression...
Docetaxel +/- ramucirumab remains the standard-of-care therapy for patients with metastatic non-small-cell lung cancer (NSCLC) after progression on platinum doublets and immune checkpoint inhibitors (ICIs). The aim of our study was to investigate whether gene mutation status associated clinical benefits from docetaxel ramucirumab. We also investigated platinum/taxane-based regimens offered a better benefit in this patient population. A total 454 were analyzed (docetaxel n=381; n=73)....
Colorectal cancer (CRC) is characterized by its high malignancy and challenging prognosis. A significant aspect of metabolic reprogramming, where lactate serves as a crucial metabolite that contributes to the development tumor microenvironment (TME). Current studies have indicated plays role in progression CRC. However, relationship between remains understudied, underscoring potential novel biomarker.
Background and Purpose The effect of antiplatelet therapy (APT) on early postoperative rehemorrhage outcomes patients with spontaneous intracerebral hemorrhage (ICH) is still unclear. This study to evaluate the preoperative APT in ICH patients. Methods was a multicenter cohort study. undergoing surgery were divided into group no (nAPT) according whether received or not. Chi-square test, t -test, Mann–Whitney U test used compare differences variables, rehematoma, between groups. Multivariate...
6111 Background: Despite aggressive local therapy, many ACC patients (~50%) develop recurrent and/or metastatic (R/M) disease. However, there is no standard of care or FDA-approved systemic therapy for this population. Based on small phase II trials, mostly including multiple salivary gland histologies, cytotoxic chemotherapy recommended symptomatic with high tumor burden, but its efficacy and impact survival in R/M remain unsubstantiated. Methods: A retrospective cohort study was conducted...
Background and purpose Spontaneous intracranial hemorrhage (ICH) patients are still at risk of postoperative ischemic complications (PICs) after surgery. In addition, the proportion receiving antiplatelet therapy (APT) in ICH increased significantly with age. This study aims to evaluate impact preoperative on PICs patients.
e21205 Background: Maintenance immunotherapy (IO) is commonly utilized in metastatic NSCLC patients (pts) who did not progress after initial treatment with platinum doublet and IO. Upon progression, docetaxel or without ramucirumab remains the of choice, which associated poor response high toxicity. We explored option rechallenge original chemotherapy agents this patient population. Methods: queried MD Anderson Cancer Center GEMINI database to perform a retrospective review pts received...
e21030 Background: Docetaxel +/- ramucirumab remains the standard of care therapy after progression on platinum doublet and immune checkpoint blockade (ICB) in patients with metastatic non-small cell lung cancer (NSCLC). However, clinical benefit from docetaxel is short-lived substantial toxicity. Additionally, whether gene mutation status impacts has not been systemically studied. In this real-world study, we aim to investigate associated docetaxel. We also explored IMPOWER150-based...
Abstract Baseline hematoma volume (HV) and growth (HG) affect the prognosis of spontaneous intracranial (ICH), but there is still a lack evidence on effects aspirin (acetylsalicylic acid, ASA) HV HG in patients with severe ICH. This study retrospectively analyzed ICH who met inclusion exclusion criterias Beijing Tiantan Hospital, Capital Medical University between January 1, 2015 July 31, 2019. Severe were divided into ASA group nASA according to usage, prior evaluated respectively. And...